By David Borenstein MD, Executive Editor, theSpineCommunity.com
What is EULAR?
EULAR is an acronym for the European Union League Against Rheumatism. It is the second largest professional rheumatologic organization. The annual meeting for this organization is taking place next week in London, England, where more than a thousand presentations and abstracts will be presented about back pain by rheumatologists from around the world.
I will be attending some of these presentations that will be of interest to the Spine Community.com. Some of the topics that will be discussed include ankylosing spondylitis (AS), psoriatic spondylitis, and osteoporosis.
The results of many clinical trials that are coming to conclusion will also be reported. Secukinamab is a new biologic recently approved in the USA for the treatment of AS, psoriasis, and psoriatic arthritis. A European study is reporting on the benefits of secukinamab in patients on the medicine for 2 years.
Another abstract is being presented on the efficacy of tofacitinib, a Janus 3 inhibitor in the treatment of AS. This drug is approved in the USA for the treatment of rheumatoid arthritis.
Other presentations will present results of new medicines for osteoporosis and the prevention of bone fractures including a new class of agents–called anti sclerostin agents– that work in ways not available with our currently available drugs like Actonel, Prolia, or Forteo.
I will report on the EULAR congress when I return.